

， ()

2015 .

.....	4
.....	6
.....	6
.....	6
.....	10
.....	10
.....	10
.....	10
.....	11
.....	12
.....	13
.....	14
.....	14
.....	15
.....	15
.....	15
.....	16
.....	16
.....	16
.....	18
.....	18
.....	21
.....	21

, / :

, / :

, ECDC,

EMBASE, MEDLINE, PubMed, ScinceDirect,

eLibrary. 5 .

(.1).

1.

1A.	
1B.	(,), (), ,
1C.	
2A.	
2B.	(,), (), ,
2C.	

Streptococcus pneumoniae –

96 *S. pneumoniae*.

80%

13 -

70-75%

20

23, 19 6

S.pneumoniae

S.pneumoniae


40%

1,6

5

0,7 1

()



.2.

(

).

1.

-	-
IgM	IgG-
--	(
	13)
--	(, 13)
-	(
	13)

7-²
 : 7 (4, 6, 9V, 14, 18, 19F)
 23F), - CRM₁₉₇,
 10- (10)

18, 19F, 23F), 10 (1, 4, 5, 6, 7F, 9V, 14, 23F), D- (*Haemophilus influenzae*) (18)

13- (13) 13 (1, 3, 4, 5, 6, 6, 7F, 9V, 14, 18, 19F, 19, 23F), CRM₁₉₇,

80,

13) 50 (5 (10

13 (6 - 17

18). 13. : 6

(vastus lateralis) 2

13 (10

23- (23) 23 (1, 2, 3, 4, 5, 6, 7F, 8, 9N, 9V, 10F, 11F, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F).

65 (2

: 2 (

	10	13
2-6	3- 1 12-15) ² 2- (3- 1 12-15) ³ 2- (
7-11	2- 1 2-	2- 1 2-
12-23	2- 2	2- 2
2-5 (24-71)		
50		

10/ 13
 12 4 3+1 8
 2+1; 12 12 - 8
 (10 / 13,) , 6 / 4-6
 50
 13
 10 13 :
 10 / 13
 (« »)

3

4

(2+1)
 (2 4,5 , 125 21.03.2014)
 2+1, 2 15

7-11 2+1: 1
 2/1 (10/ 13,
 , 6/4-6
 (10/ 13,) ;
 2 13, 12-15 , , 6/4-6
 (10/ 13,)
 12-23 : 1 10/ 13 12
 2 10/ 13 8 ;
 1 10/ 13 12 2-3 12 , 1
 , 8
 2-5 : 1 2 2-
 , 1 10/ 13, , 8

2-

(10, 13, 23)
 ()
 , (-).

5.

10

D- *Haemophilus influenzae*,

Haemophilus influenzae b.

2 4,5
 125 21.03.2014).
 2-5

15 (

5

(Prymula R, Siegrist CA, Chlibek R. et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet. 2009 Oct 17;374(9698):1339-50.)

6
 _____ 13 _____ (_____ ,
 _____ , _____ , _____
 _____), 23 _____ 8 .
 _____ , _____ , _____
 (_____), _____ ,
 _____ 23,
 _____ 13- (_____):-

_____ 2 _____ 3+1.
 _____ 24 _____ (2
 _____ 10 _____ 13 _____ 24 _____), _____ 2-5 _____ 13,
 _____ 1 _____ 13. _____ 6-18 _____ , _____ 13 _____ 19
 _____ CD4-
 _____ 13. _____ 13 _____ 8 _____ 23, _____ 23-
 _____ 5 _____ , _____ 23, _____ 13
 _____ , _____ 1 _____ 23- (_____):-

- 2 _____ , _____ 13 _____ ,
 _____ :
- _____ 2 _____ 13 _____ 3+1;
 - _____ 2-5 _____ 24 _____ 3 _____ 7 _____ 13, _____ ,
 - _____ 6-18 _____ , _____ (2 _____ 10 _____ 13); _____ 13,
 - _____ 19 _____ 13 _____ ; _____ 13.

13 _____ 23. _____ 13 _____ , _____ ,
 50 _____ , _____ 1). _____ ,
 (_____ 0,5 _____ , _____ .
 _____ 23 _____ .
 0,5 _____ .
 _____ 13 _____ 65 _____
 _____ CAPITA (_____ 1 _____).

13
 ,
 , 45,6%; 45%
 (~~14.2% 65.3%~~) 75%
 , (41.4% 90.8%).
 ,
 (CDC), (ACIP),
 :

- 13 23
 65 .
- 13.
 18-50 (. .) , 13
 , , 23, ,
- 1
 23 5 .
- 13 23
 6-12 ., 23 5 .
- 23, 13

- ,
 () ;
 - ;
 -
 ()

1-2

(20%)
 10 13
 : , 39° , ,

(. . 3), , ,

48

(37),

28

(500) , -

48 - 72

(28)

3 , ,

3 , ,

3 - , , (, ,) .

3. ()

(CIOMS)

	10	13
(<1/10 000)	, -	
(1/10000, <1/1000)	(, ; ;) ; -	- , ,
(1/1000, <1/100)	(<28) ; , ,	(,) , ,

		/ 7,0
(>1/100 <1/10)	39°C (<2)	39°C; 2.5 - 7.0 ;
(>1/10)	>38°C (<2)	2.5 - 7.0 (2-5)

1. : .
2. 30 .
() ,
2-4
3. ,
3-4 3 , -
1. : .
2. 30 .
, « » (, , , , ,
) , 2-
3. 2-6 () .
4. , - . 1-2
() 4-5 .
5. 1 - 1,5
6. - 2

, , G V.
, / /
().
2 (-) , ,).

, .
/ .
, , .
, -
(, , .),
- ()
, , .
5 , 10 ,
, .

—

—

23 —

—

13 — 13-

10 — 10-

23-